Compare Moderna, Inc. (MRNA) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Moderna, Inc. trades at $220.63 (market cap $78.65B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.68 (market cap $1.45B). The key difference: Moderna, Inc. is far larger — about 54.2× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Moderna, Inc. is trading nearer its 52-week high, Direxion NASDAQ 100 Equal Weighted Index Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days on average.
| MRNA | QQQE | |
|---|---|---|
Market Cap | $78.65B | $1.45B |
Volume | 37,373,437 | 323,568 |
Sector | Health | Broad Market / Factor |
52-Week High | $203.46 | $124.69 |
52-Week Low | $22.36 | $96.06 |
Typical Hold Time | 59 Days | 48 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
QQQE (Direxion NASDAQ-100 Equal Weighted Index ETF) trades at $121.58, down 0.25% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF provides equal-weighted exposure to NASDAQ-100 companies, reducing technology concentration from 60% to 45% compared to market-cap weighted alternatives. Recent analysis suggests QQQE offers tactical advantages over QQQ for the next twelve months due to its equal-weight methodology.
The outlook for QQQE appears favorable as equal weighting provides diversification benefits amid potential tech sector volatility. Key risks include NASDAQ concentration and market sensitivity, but the ETF's structure offers balanced exposure to large-cap growth stocks. Technical support levels at $120-121 provide near-term downside protection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
